Cholesterol and Cholesterol-Lowering Medications in COVID-19—An Unresolved Matter DOI Open Access
Thomas Grewal,

Mai Khanh Linh Nguyen,

Christa Buechler

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10489 - 10489

Published: Sept. 29, 2024

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause disease 2019 (COVID-19), a very heterogeneous symptoms. Dyslipidaemia is prevalent in at least 20% of Europeans, and dyslipidaemia before SARS-CoV-2 infection increases the risk for COVID-19 mortality by 139%. Many reports described reduced serum cholesterol levels virus-infected patients, particular those disease. The liver major organ lipid homeostasis hepatic dysfunction appears to occur one five patients infected SARS-CoV-2. Thus, infection, severity injury may be related impaired homeostasis. These observations prompted efforts assess therapeutic opportunities cholesterol-lowering medications reduce severity. majority studies implicate statins have beneficial effects on outcome COVID-19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies also shown potential protect against This review describes relationship between systemic levels, PCSK9 are summarised. Finally, lung function, first affected SARS-CoV-2, described.

Language: Английский

Identification of a Novel Antiviral Lectin against SARS-CoV-2 Omicron Variant from Shiitake-Mushroom-Derived Vesicle-like Nanoparticles DOI Creative Commons
Joshua Wiggins,

Shazeed-Ul Karim,

Baolong Liu

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(10), P. 1546 - 1546

Published: Sept. 30, 2024

Lectins are a class of carbohydrate-binding proteins that may have antiviral activity by binding to the glycans on virion surface interfere with viral entry. We identified novel lectin (named Shictin) from Shiitake mushroom (

Language: Английский

Citations

1
Cholesterol and Cholesterol-Lowering Medications in COVID-19—An Unresolved Matter DOI Open Access
Thomas Grewal,

Mai Khanh Linh Nguyen,

Christa Buechler

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10489 - 10489

Published: Sept. 29, 2024

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause disease 2019 (COVID-19), a very heterogeneous symptoms. Dyslipidaemia is prevalent in at least 20% of Europeans, and dyslipidaemia before SARS-CoV-2 infection increases the risk for COVID-19 mortality by 139%. Many reports described reduced serum cholesterol levels virus-infected patients, particular those disease. The liver major organ lipid homeostasis hepatic dysfunction appears to occur one five patients infected SARS-CoV-2. Thus, infection, severity injury may be related impaired homeostasis. These observations prompted efforts assess therapeutic opportunities cholesterol-lowering medications reduce severity. majority studies implicate statins have beneficial effects on outcome COVID-19. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies also shown potential protect against This review describes relationship between systemic levels, PCSK9 are summarised. Finally, lung function, first affected SARS-CoV-2, described.

Language: Английский

Citations

0